Search Results

OASIS-7 Trial Supports Double-Dose Clopidogrel Before PCI

September 1, 2010—A study by Shamir Mehta, MD, et al demonstrated that using a double-dose of clopidogrel reduces the risk of cardiovascular death, heart attack, or stroke by 14% compared with normal dose in patients undergoing angioplasty.

HighLife to Initiate United States Pivotal Study of TSMVR System

June 3, 2024—HighLife SAS, a France-based developer of a transseptal mitral valve replacement (TSMVR) system to treat patients with moderate-to-severe mitral regurgitation (MR), announced that the FDA granted an investigational device exemption (IDE) to initiate a United States pivotal study with its technology.